Exploiting regulatory T-cell populations for the immunotherapy of cancer.
Tumor escape from the immune system hampers effective immunotherapy for cancer. Recent evidence indicates that in cancer patients the altered activities of 2 innatelike ("natural") immunoregulatory T-cell populations could prevent the establishment of effective antitumor immune responses. These are CD4+ CD25+ (natural) regulatory T cells and invariant natural killer T cells, which normally play critical roles in orchestrating immune responses to self and nonself. Therapeutic modulation of these regulatory T-cell populations is clinically feasible and will potentially allow the induction of effective antitumor immune responses when combined with currently available immunotherapeutic strategies.
van der Vliet
Hans J J
HJ
Cancer Biology Program, Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Koon
Henry B
HB
Atkins
Michael B
MB
Balk
Steven P
SP
Exley
Mark A
MA
D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy; D053645:Interleukin-2 Receptor alpha Subunit; D007694:Killer Cells, Natural / Q000276:immunology* / Q000378:metabolism; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism; D050378:T-Lymphocytes, Regulatory / Q000276:immunology* / Q000378:metabolism; D019139:Tumor Escape
D053645:Interleukin-2 Receptor alpha Subunit